

HbA1c and the severity of acute pancreatitis: a prospective cohort study in the UK Biobank

Introduction

- In a previous meta-analysis, we discovered a significant association between elevated HbA1c levels and a higher risk of severe acute pancreatitis (AP) (**OR = 2.14, 95% CI 1.32-3.48**).
- To further investigate this relationship, we conducted a new study using the UK Biobank – a dataset comprising clinical information from over half a million participants in England, Wales, and Scotland [1].

Aims

- To determine the association between HbA1c and AP severity
- To determine the association between HbA1c and the development of local pancreatic complications
- To identify associations between HbA1c and systemic complications including mortality

Methods

Identification: Cases of AP were identified using ICD-10 and ICD-9 codes.

Severity Stratification: Defined by the development of complications within 30 days of diagnosis, or any significant procedures related to their diagnosis were performed, identified through OPCS codes.


Analyses:

- Patients were divided into three groups based on HbA1c levels and severe the incidence of cases, local/systemic complications, and mortality rates were examined
- Statistical significance was assessed using the Cochran-Armitage test and multivariable logistic regression for patients with and without diabetes.

Results

A significant increasing trend in AP cases was observed with rising HbA1c levels ($p=0.0126$).

Figure 1: Plot of SAP cases amongst each HbA1c group



However, after accounting for variables like age and comorbid diseases, HbA1c did not influence the severity of AP (adjusted OR 1.02, $p=0.656$), local complications (adjusted OR 0.94, $p=0.545$), or systemic complications (adjusted OR 1.00, $p=0.991$).

Table 1: Regression analysis for SAP

Variable	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
HbA1c (mmol/L) per 5 unit increase	1.10 (1.03 – 1.17)	0.006	1.02 (0.93 – 1.11)	0.656
Age (years) per 5 year increase	1.20 (1.11–1.30)	<0.0001	1.14 (1.05 – 1.24)	0.002
Sex	1.42 (1.12–1.80)	0.003	1.25 (0.98 – 1.61)	0.076
BMI	1.00 (0.98–1.02)	0.924	0.99 (0.97 – 1.02)	0.646
Current smoker	1.28 (0.92–1.77)	0.143	1.18 (0.82 – 1.70)	0.372
Alcohol dependent	1.73 (1.03–2.92)	0.039	1.51 (0.86 – 2.66)	0.149
COPD	2.03 (1.46–2.83)	<0.0001	1.41 (0.97 – 2.03)	0.068
Diabetes	1.63 (1.23–2.18)	0.001	1.26 (0.87 – 1.84)	0.225
CKD	2.28 (1.63–3.20)	<0.0001	1.62 (1.12 – 2.34)	0.010
CVA	1.87 (1.20–2.91)	0.006	1.21 (0.75 – 1.95)	0.426
MI	1.81 (1.27–2.59)	0.001	1.11 (0.71 – 1.73)	0.656
CHF	3.10 (2.12–4.54)	<0.0001	2.17 (1.40 – 3.37)	0.001
PVD	1.64 (1.16–2.30)	0.005	0.92 (0.60 – 1.41)	0.709

A 5 mmol .l-1 increase in HbA1c did raise mortality odds in non-diabetic patients (adjusted OR 1.47, $p=0.030$), suggesting its potential as a prognostic indicator for this group. Congestive heart failure and chronic kidney disease consistently elevated odds of a worse prognosis in AP cases.

Table 2: Regression analysis for mortality in patients without diabetes

Variable	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
HbA1c (mmol.l ⁻¹) per 5 unit increase	1.62 (1.18 – 2.23)	0.003	1.47 (1.04 – 2.09)	0.030
Age (years) per 5 year increase	1.44 (1.20 – 1.73)	<0.0001	1.37 (1.12 – 1.67)	0.002
Sex	1.28 (0.78 – 2.10)	0.321	1.13 (0.66 – 1.93)	0.659
BMI	1.02 (0.98 – 1.07)	0.297	1.03 (0.98 – 1.08)	0.303
Current smoker	1.83 (1.01 – 3.32)	0.047	2.30 (1.16 – 4.57)	0.017
Alcohol dependent	1.19 (0.36 – 3.94)	0.771	1.15 (0.32 – 4.17)	0.827
COPD	1.90 (0.97 – 3.73)	0.061	0.99 (0.46 – 2.11)	0.973
CKD	3.34 (1.82 – 6.15)	<0.0001	1.98 (1.00 – 3.92)	0.048
CVA	0.55 (0.13 – 2.31)	0.416	0.27 (0.06 – 1.23)	0.091
MI	2.73 (1.44 – 5.17)	0.002	1.50 (0.66 – 3.41)	0.338
CHF	5.15 (2.71 – 9.79)	<0.0001	4.02 (1.84 – 8.80)	<0.0001
PVD	1.64 (0.82 – 3.29)	0.166	0.58 (0.24 – 1.42)	0.230

Discussion

- Regression analyses highlighted the fact that a myriad of factors affect AP outcomes
- Comparison with existing literature reveals a mosaic of sometimes conflicting evidence on HbA1c's relationship with AP[2][3]
- CKD and CHF emerged as pivotal conditions influencing AP severity and outcomes, even surpassing the impact of diabetes.

Strengths/limitations

- ✓ Pioneering study exploring the impact of HbA1c on AP
- ✓ Made strong efforts to reduce the effects of confounding
- ✓ To date is the largest study assessing the relationship
- ✗ The UK Biobank lacks AP severity measures, necessitating our independent assessment and introducing the risk of misclassification.
- ✗ The study depends on the accuracy of reporting by Biobank clinicians, thus specific complications may have been missed if not actively sought for.

Conclusions

- High HbA1c levels may be more aptly viewed as an indicator of poor overall health
- Elevated HbA1c remains potentially useful in identifying patients without diabetes who are at a heightened risk of AP mortality
- A comprehensive international cohort study with rigorous diagnostic protocols for local complications and proactive measures to include participants with higher HbA1c values should be performed to definitively assess the relationship.